Proposed
Bill · 119th Congress · HR 8857
Next GEN Act of 2026
Refreshed 4 h ago
Introduced 2026-05-15Topic: health careSummary
AI-generated summary, report an errorThis bill changes the Medicare Drug Price Negotiation Program for a group of drugs called engineered cyclic peptides. Under current law, a drug of this kind can become eligible for price negotiation 7 years after approval; the bill would change that waiting period to 11 years for engineered cyclic peptides. It defines an engineered cyclic peptide as a lab-made chain of no more than 40 amino acids with at least one ring structure, found through a genetic library screening method, and taken by mouth, inhaled, or otherwise self-administered. The change would apply to drug selection lists published on or after the bill becomes law.
Sponsors
- Joseph D. Morelle Democrat sponsor
- 4 cosponsors
Action history
| Date | Chamber | Action | Status effect |
|---|---|---|---|
| 2026-05-15 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. | refer |
| 2026-05-15 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. | refer |
| 2026-05-15 | Introduced in House | introduce | |
| 2026-05-15 | Introduced in House | introduce |